Mitsuhashi S, et al. (2005) Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. Mol Cell Biochem 269, 183-7 15786731

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S782-p - gp130 (human) ▲

Modsite: QVFSRsEsTQPLLDS SwissProt Entrez-Gene Orthologous residues gp130 (human): S782‑p, gp130 iso2 (human): ‑, gp130 iso3 (human): S721‑p, gp130 (mouse): S780‑p, gp130 (rat): S781‑p Characterization Methods used to characterize site in vivo:  phospho-antibody Relevant cell lines - cell types - tissues:  HepG2 (hepatic) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme PHOSPHATASE PPP2CA (human) Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes okadaic_acid increase MG115 okadaic_acid augment treatment-induced increase tautomycin no change compared to control Downstream Regulation Effect of modification (function):  protein degradation

Y705-p - STAT3 (human) ▲

Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene Orthologous residues STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p Characterization Methods used to characterize site in vivo:  phospho-antibody Relevant cell lines - cell types - tissues:  HepG2 (hepatic) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IL-6 increase okadaic_acid IL-6 inhibit treatment-induced increase